Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.

Jørgensen MB, Idorn T, Knop FK, Holst JJ, Hornum M, Feldt-Rasmussen B.

Nephrol Dial Transplant. 2014 Oct 15. pii: gfu327. [Epub ahead of print]

PMID:
25319937
[PubMed - as supplied by publisher]
2.

Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Søgaard B, Holst JJ, Szecsi PB, Lublin H.

J Clin Psychiatry. 2014 Sep;75(9):e899-905. doi: 10.4088/JCP.13m08820.

PMID:
25295432
[PubMed - in process]
Free Article
3.

[Duodenal-jejunal bypass sleeve - a potential alternative to bariatric surgery?]

Rohde U, Gylvin S, Vilmann P, Friis SU, Langholz E, Vilsbøll T, Knop FK.

Ugeskr Laeger. 2014 Sep 8;176(37). pii: V01140053. Danish.

PMID:
25294038
[PubMed - as supplied by publisher]
4.

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.

Sonne DP, Lund A, Faber J, Holst JJ, Vilsbøll T, Knop FK.

Endocr Connect. 2014 Dec;3(4):193-9. doi: 10.1530/EC-14-0088. Epub 2014 Oct 2.

PMID:
25277744
[PubMed]
Free Article
5.
6.

Glucose-dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans.

Nissen A, Christensen M, Knop FK, Vilsbøll T, Holst JJ, Hartmann B.

J Clin Endocrinol Metab. 2014 Aug 21:jc20142547. [Epub ahead of print]

PMID:
25144635
[PubMed - as supplied by publisher]
7.

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial.

Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.

J Eur Acad Dermatol Venereol. 2014 Aug 20. doi: 10.1111/jdv.12629. [Epub ahead of print]

PMID:
25139195
[PubMed - as supplied by publisher]
8.

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.

Expert Opin Drug Discov. 2014 Oct;9(10):1223-51. doi: 10.1517/17460441.2014.942638. Epub 2014 Aug 14.

PMID:
25119443
[PubMed - in process]
9.

Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes.

Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2014 Jul 22. pii: DB_140440. [Epub ahead of print]

PMID:
25053587
[PubMed - as supplied by publisher]
10.

Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.

Brønden A, Hansen M, Sonne DP, Rohde U, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2014 Jul 9. doi: 10.1111/dom.12355. [Epub ahead of print]

PMID:
25041567
[PubMed - as supplied by publisher]
11.

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.

Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsbøll T, Jørgensen NB, Hartmann B, Deacon CF, Dragsted LO, Holst JJ.

Diabetes Obes Metab. 2014 Nov;16(11):1155-64. doi: 10.1111/dom.12352. Epub 2014 Jul 22.

PMID:
25041349
[PubMed - in process]
12.

The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract.

Rhee NA, Vilmann P, Hassan H, Hendel JW, Holst JJ, Vilsbøll T, Knop FK.

Scand J Gastroenterol. 2014 Sep;49(9):1143-9. doi: 10.3109/00365521.2014.934912. Epub 2014 Jul 7.

PMID:
24998781
[PubMed - in process]
13.

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.

Sonne DP, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK.

Eur J Endocrinol. 2014 Oct;171(4):407-19. doi: 10.1530/EJE-14-0309. Epub 2014 Jul 1.

PMID:
24986531
[PubMed - in process]
14.

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

Rhee NA, Østoft SH, Holst JJ, Deacon CF, Vilsbøll T, Knop FK.

Eur J Endocrinol. 2014 Sep;171(3):353-62. doi: 10.1530/EJE-14-0314. Epub 2014 Jun 16.

PMID:
24935932
[PubMed - indexed for MEDLINE]
15.

Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.

Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T.

Diabetes Care. 2014 Jul;37(7):1797-805. doi: 10.2337/dc13-3007.

PMID:
24929431
[PubMed - in process]
16.

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

Wewer Albrechtsen NJ, Hartmann B, Veedfald S, Windeløv JA, Plamboeck A, Bojsen-Møller KN, Idorn T, Feldt-Rasmussen B, Knop FK, Vilsbøll T, Madsbad S, Deacon CF, Holst JJ.

Diabetologia. 2014 Sep;57(9):1919-26. doi: 10.1007/s00125-014-3283-z. Epub 2014 Jun 3.

PMID:
24891019
[PubMed - in process]
17.

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.

Knop FK, Lund A, Madsbad S, Holst JJ, Krarup T, Vilsbøll T.

BMC Res Notes. 2014 May 31;7:326. doi: 10.1186/1756-0500-7-326.

PMID:
24885055
[PubMed - in process]
Free PMC Article
18.

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.

Bagger JI, Knop FK, Lund A, Holst JJ, Vilsbøll T.

Diabetologia. 2014 Aug;57(8):1720-5. doi: 10.1007/s00125-014-3264-2. Epub 2014 May 31.

PMID:
24879388
[PubMed - in process]
19.

Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.

Sonne DP, Hansen M, Knop FK.

Eur J Endocrinol. 2014 Aug;171(2):R47-65. doi: 10.1530/EJE-14-0154. Epub 2014 Apr 23. Review.

PMID:
24760535
[PubMed - indexed for MEDLINE]
Free Article
20.

Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.

Idorn T, Knop FK, Jørgensen MB, Christensen M, Holst JJ, Hornum M, Feldt-Rasmussen B.

J Clin Endocrinol Metab. 2014 Jul;99(7):2457-66. doi: 10.1210/jc.2013-3809. Epub 2014 Apr 8.

PMID:
24712563
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk